Frontiers in Pharmacology (Oct 2022)
Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic
- José Diogo S. Souza,
- Antonio W. Zuardi,
- Antonio W. Zuardi,
- Francisco S. Guimarães,
- Francisco S. Guimarães,
- Flávia de Lima Osório,
- Flávia de Lima Osório,
- Sonia Regina Loureiro,
- Alline Cristina Campos,
- Jaime E. C. Hallak,
- Jaime E. C. Hallak,
- Rafael G. Dos Santos,
- Rafael G. Dos Santos,
- Isabella Lara Machado Silveira,
- Karina Pereira-Lima,
- Karina Pereira-Lima,
- Julia Cozar Pacheco,
- Juliana Mayumi Ushirohira,
- Rafael Rinaldi Ferreira,
- Karla Cristinne Mancini Costa,
- Davi Silveira Scomparin,
- Franciele Franco Scarante,
- Isabela Pires-Dos-Santos,
- Raphael Mechoulam,
- Flávio Kapczinski,
- Flávio Kapczinski,
- Flávio Kapczinski,
- Benedito A. L. Fonseca,
- Danillo L. A. Esposito,
- Maristela Haddad Andraus,
- José Alexandre S. Crippa,
- José Alexandre S. Crippa
Affiliations
- José Diogo S. Souza
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Antonio W. Zuardi
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Antonio W. Zuardi
- National Institute for Science and Technology—Translational Medicine, Ribeirão Preto, Brazil
- Francisco S. Guimarães
- National Institute for Science and Technology—Translational Medicine, Ribeirão Preto, Brazil
- Francisco S. Guimarães
- Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Flávia de Lima Osório
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Flávia de Lima Osório
- National Institute for Science and Technology—Translational Medicine, Ribeirão Preto, Brazil
- Sonia Regina Loureiro
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Alline Cristina Campos
- Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Jaime E. C. Hallak
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Jaime E. C. Hallak
- National Institute for Science and Technology—Translational Medicine, Ribeirão Preto, Brazil
- Rafael G. Dos Santos
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Rafael G. Dos Santos
- National Institute for Science and Technology—Translational Medicine, Ribeirão Preto, Brazil
- Isabella Lara Machado Silveira
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Karina Pereira-Lima
- University of Michigan Medical School, Ann Arbor, IN, United States
- Karina Pereira-Lima
- Department of Psychiatry, Federal University of São Paulo, São Paulo, São Paulo, Brazil
- Julia Cozar Pacheco
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Juliana Mayumi Ushirohira
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Rafael Rinaldi Ferreira
- Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Karla Cristinne Mancini Costa
- Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Davi Silveira Scomparin
- Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Franciele Franco Scarante
- Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Isabela Pires-Dos-Santos
- Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Raphael Mechoulam
- The Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel
- Flávio Kapczinski
- National Institute for Science and Technology—Translational Medicine, Ribeirão Preto, Brazil
- Flávio Kapczinski
- Department of Psychiatry and Behavioural Neurosciences, McMaster University and St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
- Flávio Kapczinski
- Department of Psychiatry, Faculty of Medicine, Graduate Program in Psychiatry and Behavioral Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- Benedito A. L. Fonseca
- Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Danillo L. A. Esposito
- Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- Maristela Haddad Andraus
- 0Chromatox Laboratory Ltd São Paulo, Brazil
- José Alexandre S. Crippa
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
- José Alexandre S. Crippa
- National Institute for Science and Technology—Translational Medicine, Ribeirão Preto, Brazil
- DOI
- https://doi.org/10.3389/fphar.2022.856846
- Journal volume & issue
-
Vol. 13
Abstract
Objective: To assess whether the effects of oral administration of 300 mg of Cannabidiol (CBD) for 28 days on mental health are maintained for a period after the medication discontinuation.Methods: This is a 3-month follow-up observational and clinical trial study. The data were obtained from two studies performed simultaneously by the same team in the same period and region with Brazilian frontline healthcare workers during the COVID-19 pandemic. Scales to assess emotional symptoms were applied weekly, in the first month, and at weeks eight and 12.Results: The primary outcome was that, compared to the control group, a significant reduction in General Anxiety Disorder-7 Questionnaire (GAD-7) from baseline values was observed in the CBD group on weeks two, four, and eight (Within-Subjects Contrasts, time-group interactions: F1-125 = 7.67; p = 0.006; ηp2 = 0.06; F1-125 = 6.58; p = 0.01; ηp2 = 0.05; F1-125 = 4.28; p = 0.04; ηp2 = 0.03, respectively) after the end of the treatment.Conclusions: The anxiolytic effects of CBD in frontline health care professionals during the COVID-19 pandemic were maintained up to 1 month after the treatment discontinuation, suggesting a persistent decrease in anxiety in this group in the real world. Future double-blind placebo-controlled clinical trials are needed to confirm the present findings and weigh the benefits of CBD therapy against potential undesired or adverse effects.
Keywords
